Nuclear factor-κB regulates expression of platelet phospholipase C-β2 (PLCB2)

Summary

Phospholipase C (PLC)-β2 (gene PLCB2) is a critical regulator of platelet responses upon activation. Mechanisms regulating of PLC-β2 expression in platelets/MKs are unknown. Our studies in a patient with platelet PLC-β2 deficiency revealed the PLCB2 coding sequence to be normal and decreased platelet PLC-β2 mRNA, suggesting a defect in transcriptional regulation. PLCB2 5’- upstream region of the patient revealed a heterozygous 13 bp deletion (-1645/-1633 bp) encompassing a consensus sequence for nuclear factor-κB (NF-κB). This was subsequently detected in three of 50 healthy subjects. To understand the mechanisms regulating PLC-β2, we studied the effect of this variation in the PLCB2. Gel-shift studies using nuclear extracts from human erythroleukaemia (HEL) cells or recombinant p65 showed NF-κB binding to oligonucleotide with NF-κB site; in luciferase reporter studies its deletion reduced PLCB2 promoter activity. PLCB2 expression was decreased by siRNA knockdown of NF-κB p65 subunit and increased by p65 overexpression. By immunoblotting platelet PLC-β2 in 17 healthy subjects correlated with p65 (r=0.76, p=0.0005). These studies provide the first evidence that NF-kB regulates MK/platelet PLC-β2 expression. This interaction is important because of the major role of PLC-β2 in platelet activation and of NF-κB in processes, including inflammation and atherosclerosis, where both are intimately involved.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Megakaryocytess - nuclear factor-κB - phospholipase C-β2 - platelet function defect - platelets

• References

• 1 Brass LF, Stalker TJ, Zhu L, Woulfe DS. Signal transduction during platelet plug formation. In Michelson AD. editor. Platelets. Second ed:. Academic Press; 2007: 319-346.
• 2 Rhee SG, Bae YS. Regulation of phosphoinositide-specific phospholipase C isozymes. J Biol Chem 1997; 272: 15045-15048.
• 3 Lee SB, Rao AK, Lee KH. et al. Decreased expression of phospholipase C-beta 2 isozyme in human platelets with impaired function. Blood 1996; 88: 1684-1691.
• 4 Rao AK, Kowalska MA, Disa J. Impaired cytoplasmic ionized calcium mobilisation in inherited platelet secretion defects. Blood 1989; 74: 664-672.
• 5 Yang X, Sun L, Ghosh S. et al. Human platelet signalling defect characterized by impaired production of inositol-1,4,5-triphosphate and phosphatidic acid and diminished Pleckstrin phosphorylation: evidence for defective phospholipase C activation. Blood 1996; 88: 1676-1683.
• 6 Mao GF, Vaidyula VR, Kunapuli SP. et al. Lineage-specific defect in gene expression in human platelet phospholipase C-beta2 deficiency. Blood 2002; 99: 905-911.
• 7 Kang CD, Han CS, Kim KW. et al. Activation of NF-kappaB mediates the PMA-induced differentiation of K562 cells. Cancer Lett 1998; 132: 99-106.
• 8 Kim KW, Kim SH, Lee EY. et al. Extracellular signal-regulated kinase/90-KDA ribosomal S6 kinase/nuclear factor-kappa B pathway mediates phorbol 12-myr-istate 13-acetate-induced megakaryocytic differentiation of K562 cells. J Biol Chem 2001; 276: 13186-13191.
• 9 Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?. J Clin Invest 2001; 107: 255-264.
• 10 Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. On-cogene 2006; 25: 6680-6684.
• 11 Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008; 08: 837-848.
• 12 Rondina MT, Weyrich AS, Zimmerman GA. Platelets as cellular effectors of inflammation in vascular diseases. Circ Res 2013; 112: 1506-1519.
• 13 Kumar A, Takada Y, Boriek AM. et al. Nuclear factor-kappaB: its role in health and disease. J Mol Med 2004; 82: 434-448.
• 14 Strauss WM. Preparation of genomic DNA from mammalian tissue. Curr Protoc Mol Biol. 1994. 1. Philadelphia: John Wiley and Sons; 21-23.
• 15 Liptay S, Schmid RM, Nabel EG. et al. Transcriptional regulation of NF-kappa B2: evidence for kappa B-mediated positive and negative autoregulation. Mol Cell Biol 1994; 14: 7695-7703.
• 16 Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-3450.
• 17 Ballard DW, Dixon EP, Peffer NJ. et al. The 65-kDa subunit of human NF-kappa B functions as a potent transcriptional activator and a target for v-Rel-mediated repression. Proc Natl Acad Sci USA 1992; 89: 1875-1879.
• 18 Makeyev AV, Bayarsaihan D. Alternative splicing and promoter use in TFII-I genes. Gene 2009; 433: 16-25.
• 19 Roy AL. Biochemistry and biology of the inducible multifunctional transcription factor TFII-I. Gene 2001; 274: 1-13.
• 20 Roy AL. Signal-induced functions of the transcription factor TFII-I. Biochim Biophys Acta 2007; 1769: 613-621.
• 21 Cupit LD, Schmidt VA, Gnatenko DV. et al. Expression of protease activated receptor 3 (PAR3) is upregulated by induction of megakaryocyte phenotype in human erythroleukemia (HEL) cells. Exp Hematol 2004; 32: 991-999.
• 22 Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
• 23 von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 27-40.
• 24 Wang Z, Liu B, Wang P. et al. Phospholipase C beta3 deficiency leads to macro-phage hypersensitivity to apoptotic induction and reduction of atherosclerosis in mice. J Clin Invest 2008; 118: 195-204.
• 25 Al-Attas OS, Al-Daghri NM, Al-Rubeaan K. et al. Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. Cardiovasc Diabetol 2009; 08: 20.
• 26 Singh A, Boden G, Rao AK. Tissue factor Toll-like receptor (TLR)4 in hy-perglycaemia-hyperinsulinaemia. Effects in healthy subjects, and type 1 and type 2 diabetes mellitus. Thromb Haemost 2015; 113: 750-758.
• 27 Spinelli SL, Casey AE, Pollock SJ. et al. Platelets and megakaryocytes contain functional nuclear factor-kappaB. Arterioscler Thromb Vasc Biol 2010; 30: 591-598.
• 28 Zhang Y, Sun S, Wang Z. et al. Signalling by the Mpl receptor involves IKK and NF-kappaB. J Cell Biochem 2002; 85: 523-535.
• 29 Romanelli RG, Petrai I, Robino G. et al. Thrombopoietin stimulates migration and activates multiple signalling pathways in hepatoblastoma cells. Am J Physiol Gastrointest Liver Physiol 2006; 290: G120-128.
• 30 Rao AK, Freishtat RJ, Jalagadugula G. et al. Alterations in insulin-signalling and coagulation pathways in platelets during hyperglycemia-hyperinsulinemia in healthy non-diabetic subject. Thromb Res 2014; 134: 704-710.
• 31 Liu F, Morris S, Epps J. et al. Demonstration of an activation regulated NF-kap-paB/I-kappaBalpha complex in human platelets. Thromb Res 2002; 106: 199-203.
• 32 Malaver E, Romaniuk MA, D’Atri LP. et al. NF-kappaB inhibitors impair platelet activation responses. J Thromb Haemost 2009; 07: 1333-1343.
• 33 Schattner M. Role of NF-kappaB pathway on platelet activation. Circ Res 2013; 113: e92.
• 34 Weyrich AS, Dixon DA, Pabla R. et al. Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proc Natl Acad Sci USA 1998; 95: 5556-5561.
• 35 Zimmerman GA, Weyrich AS. Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function. Arterioscler Thromb Vasc Biol 2008; 28: s17-24.
• 36 Songdej N, Rao AK. Hematopoietic transcription factor mutations and inherited platelet dysfunction. F1000 Prime Rep 2015; 07: 66.